Home Cart Sign in  
Chemical Structure| 307002-71-7 Chemical Structure| 307002-71-7

Structure of CL-82198
CAS No.: 307002-71-7

Chemical Structure| 307002-71-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CL-82198 is a selective inhibitor of MMP-13.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CL-82198

CAS No. :307002-71-7
Formula : C17H22N2O3
M.W : 302.37
SMILES Code : O=C(C1=CC2=CC=CC=C2O1)NCCCCN3CCOCC3
MDL No. :MFCD12828877

Safety of CL-82198

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rat hepatic stellate cells 10 μM 48 h To examine the effect of MMP-13 inhibition on CTGF and TGF-β1 protein levels, results showed that inhibition of MMP-13 significantly decreased the protein levels of CTGF and its C-terminal fragments as well as active TGF-β1. J Cell Mol Med. 2017 Dec;21(12):3821-3835

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Medaka (Oryzias latipes) Osteoporosis model Immersion 300 μM Continuous treatment from 7 dpf to 12 dpf To evaluate the effect of MMP13 inhibitor CL-82198 on bone resorption. Results showed that CL-82198 treatment significantly reduced bone resorption, with fewer lesions in vertebral centra and mostly intact neural arches. Front Cell Dev Biol. 2022 Feb 21;10:775512
Zebrafish Streptozotocin-induced diabetic neuropathic pain model Exposure in water 10 µM 10 consecutive days To evaluate the reversal effect of CL-82198 on diabetic neuropathic pain, results showed that CL-82198 ameliorated neuralgic behavioral parameters and biochemical changes. Pharmaceuticals (Basel). 2023 Jan 22;16(2):157
Mice High-fat/high-sugar diet-induced diabetic neuropathy model Intraperitoneal injection 5 mg/kg Every other day for 14 days To evaluate the therapeutic effect of MMP-13 inhibitor on diabetic neuropathy, results showed that CL-82198 significantly improved tactile sensitivity in mice J Diabetes Complications. 2018 Mar;32(3):249-257
Zebrafish Diabetic cerebrovascular damage-associated Alzheimer’s disease model Not specified 10 μM 21 consecutive days To evaluate the effect of CL-82198 in a diabetic cerebrovascular damage-associated Alzheimer’s disease model, results showed that CL-82198 improved cognitive dysfunction. Mar Drugs. 2023 Jul 31;21(8):433
Sprague-Dawley rats Trauma and hemorrhagic shock model Intratracheal instillation 100 μM Pretreatment before trauma Pretreatment with MMP-13 inhibitor significantly attenuated acute lung injury following trauma/hemorrhagic shock, as reflected by a significant reduction in BAL protein content. Crit Care Med. 2012 Sep;40(9):2647-53

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.54mL

3.31mL

1.65mL

33.07mL

6.61mL

3.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories